company background image
ICPT

Intercept Pharmaceuticals NasdaqGS:ICPT Stock Report

Last Price

US$13.81

Market Cap

US$410.3m

7D

2.1%

1Y

-32.5%

Updated

30 Jun, 2022

Data

Company Financials +
ICPT fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

ICPT Stock Overview

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.

Intercept Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Intercept Pharmaceuticals
Historical stock prices
Current Share PriceUS$13.81
52 Week HighUS$20.64
52 Week LowUS$10.81
Beta1.26
1 Month Change-23.70%
3 Month Change-19.00%
1 Year Change-32.54%
3 Year Change-82.84%
5 Year Change-88.64%
Change since IPO-28.81%

Recent News & Updates

May 23

Intercept: Increase Of Ocaliva Sales And A Few Catalysts

Final data from the phase 3 REGENERATE study, using Ocaliva for the treatment of patients with NASH fibrosis, is expected any day now. If all goes well with clinical data, Intercept expects a pre-submission meeting with the FDA in June of 2022. Results from the phase 3 REVERSE study using Ocaliva for the treatment of patients with compensated cirrhosis due to NASH are expected in Q3 of 2022. Two studies are being done testing the fixed dose combination of Ocaliva and bezafibrate for the treatment of patients with primary biliary cholangitis. Licensing deal made with Advanz Pharma for Ocaliva brought in $405 million as an upfront payment and the potential to earn $45 million upon a condition being met; from there, it will be eligible for royalties on net sales.

Shareholder Returns

ICPTUS BiotechsUS Market
7D2.1%3.8%1.6%
1Y-32.5%-25.8%-20.8%

Return vs Industry: ICPT underperformed the US Biotechs industry which returned -25.8% over the past year.

Return vs Market: ICPT underperformed the US Market which returned -20.8% over the past year.

Price Volatility

Is ICPT's price volatile compared to industry and market?
ICPT volatility
ICPT Average Weekly Movement10.9%
Biotechs Industry Average Movement13.1%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: ICPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ICPT's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002437Jerry Dursohttps://www.interceptpharma.com

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development.

Intercept Pharmaceuticals Fundamentals Summary

How do Intercept Pharmaceuticals's earnings and revenue compare to its market cap?
ICPT fundamental statistics
Market CapUS$410.34m
Earnings (TTM)-US$68.29m
Revenue (TTM)US$370.39m

1.1x

P/S Ratio

-6.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ICPT income statement (TTM)
RevenueUS$370.39m
Cost of RevenueUS$3.05m
Gross ProfitUS$367.34m
Other ExpensesUS$435.63m
Earnings-US$68.29m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.30
Gross Margin99.18%
Net Profit Margin-18.44%
Debt/Equity Ratio-192.8%

How did ICPT perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ICPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ICPT?

Other financial metrics that can be useful for relative valuation.

ICPT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA-21.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ICPT's PS Ratio compare to its peers?

ICPT PS Ratio vs Peers
The above table shows the PS ratio for ICPT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average109.8x
RDUS Radius Health
2.3x9.3%US$493.6m
AFMD Affimed
10.3x43.0%US$413.5m
GERN Geron
424.7x73.8%US$585.0m
CHRS Coherus BioSciences
1.8x33.8%US$560.5m
ICPT Intercept Pharmaceuticals
1.1x23.3%US$410.3m

Price-To-Sales vs Peers: ICPT is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (109.8x).


Price to Earnings Ratio vs Industry

How does ICPT's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: ICPT is good value based on its Price-To-Sales Ratio (1.1x) compared to the US Biotechs industry average (13.3x)


Price to Sales Ratio vs Fair Ratio

What is ICPT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ICPT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.1x
Fair PS Ratio8.6x

Price-To-Sales vs Fair Ratio: ICPT is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (8.6x).


Share Price vs Fair Value

What is the Fair Price of ICPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ICPT ($13.81) is trading below our estimate of fair value ($301.81)

Significantly Below Fair Value: ICPT is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ICPT's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Intercept Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


73.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ICPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: ICPT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ICPT is expected to become profitable in the next 3 years.

Revenue vs Market: ICPT's revenue (23.3% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: ICPT's revenue (23.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ICPT's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Intercept Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


18.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ICPT is currently unprofitable.

Growing Profit Margin: ICPT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ICPT is unprofitable, but has reduced losses over the past 5 years at a rate of 18.2% per year.

Accelerating Growth: Unable to compare ICPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ICPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: ICPT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Intercept Pharmaceuticals's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ICPT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ICPT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ICPT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ICPT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ICPT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ICPT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Intercept Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ICPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ICPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ICPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ICPT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ICPT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Jerry Durso (53 yo)

1.42yrs

Tenure

US$7,870,354

Compensation

Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...


CEO Compensation Analysis

Compensation vs Market: Jerry's total compensation ($USD7.87M) is above average for companies of similar size in the US market ($USD2.86M).

Compensation vs Earnings: Jerry's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ICPT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: ICPT's board of directors are considered experienced (8.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Intercept Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Intercept Pharmaceuticals, Inc.
  • Ticker: ICPT
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$410.337m
  • Shares outstanding: 29.71m
  • Website: https://www.interceptpharma.com

Number of Employees


Location

  • Intercept Pharmaceuticals, Inc.
  • 10 Hudson Yards
  • 37th Floor
  • New York
  • New York
  • 10001
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/30 00:00
End of Day Share Price2022/06/30 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.